Teva Pharmaceutical (NYSE:TEVA) said today that it launched the AirDuo RespiClick inhalation therapy and its authorized generic in the U.S. for asthma patients who are uncontrolled on an inhaled corticosteroid.
AirDuo RespiClick and the generic are fixed-dose combination therapies contained fluticasone propionate and salmeterol – the same active ingredients as Advair. The therapies are delivered using Teva’s breath-activated RespiClick inhaler.
Get the full story at our sister site, Drug Delivery Business News.
The post Teva launches AirDuo RespiClick, generic inhaled asthma therapies appeared first on MassDevice.